Adma Biologics reported $58.74M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Adma Biologics USD 58.74M 14.75M Sep/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Minerva Neurosciences USD -4.36M 1.71M Sep/2024
Novavax USD -117.12M 55.66M Sep/2024
Omeros USD -47.96M 7.39M Sep/2023
Takeda JPY 448.13B 173.98B Dec/2025